Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma

Current treatment strategy for kidney renal clear cell carcinoma (KIRC) is limited. Tumor-associated antigens, especially neoantigen-based personalized mRNA vaccines represent new strategies and manifest clinical benefits in solid tumors, but only a small proportion of patients could benefit from th...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hang, Zheng, Xiaonan, Zhang, Shiyu, Yi, Xianyanling, Zhang, Tianyi, Wei, Qiang, Li, Hong, Ai, Jianzhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645676/
https://www.ncbi.nlm.nih.gov/pubmed/34872567
http://dx.doi.org/10.1186/s12943-021-01465-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645676/
https://www.ncbi.nlm.nih.gov/pubmed/34872567
http://dx.doi.org/10.1186/s12943-021-01465-w

Ejemplares similares